<DOC>
	<DOCNO>NCT02742519</DOCNO>
	<brief_summary>To evaluate efficacy ivacaftor treatment , measure lung clearance index ( LCI ) , subject cystic fibrosis ( CF ) specify CF transmembrane conductance regulator ( CFTR ) gate mutation</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Ivacaftor Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have Specified CFTR Gating Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Male female confirm diagnosis CF . Must 1 follow CFTR gate mutation least 1 allele : G551D , G178R , S549N , S549R , G551S , G1244E , S1251N , S1255P , G1349D . Hematology , serum chemistry , coagulation Screening clinically significant abnormality concomitant diagnosis would interfere LCI CT scan study assessment , judge investigator . An acute upper low respiratory infection , pulmonary exacerbation , change therapy ( include antibiotic ) pulmonary disease within 4 week Day 1 Any clinically significant laboratory abnormality Screening Visit would interfere study assessment pose undue risk subject ( opinion investigator ) Abnormal liver function , Screening , define ≥3 × upper limit normal ( ULN ) , 3 following : serum aspartate transaminase ( AST ) , serum alanine transaminase ( ALT ) , gammaglutamyl transpeptidase ( GGT ) , serum alkaline phosphatase ( ALP ) , total bilirubin History solid organ hematological transplantation Any clinically significant `` nonCFrelated '' illness within 2 week Day 1 Use moderate strong inducer inhibitor cytochrome P450 ( CYP ) 3A within 2 week Day 1 Participation clinical study involve administration either investigational marketed drug within 30 day 5 terminal halflives ( whichever longer determine local requirement ) Screening</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>